2. Garje R, Rumble RB, Parikh RA. Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation. J Clin Oncol. 2022 Nov 1;40(31):3664-3666. doi: 10.1200/JCO.22.01865. Epub 2022 Sep 16. PMID: 36112960. 3. Hofman MS, Emmet...
1. Sartor O, de Bono J, Chi KN, et al: Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091-1103, 2021 2. Garje R, Rumble RB, Parikh RA. Systemic Therapy Update on 177Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO...
[1]https://www.urotoday.com/conference-highlights/aua-2024/aua-2024-prostate-cancer
来源 [1]https://www.urotoday.com/conference-highlights/aua-2024/aua-2024-prostate-cancer
放射性同位素的辐射仅在很短的距离内发挥作用,以限制对周围细胞的损害。(生物谷Bioon.com) 原文出处:Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study...
放射性同位素的辐射仅在很短的距离内发挥作用,以限制对周围细胞的损害。(生物谷Bioon.com) 原文出处:Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study...
放射性同位素的辐射仅在很短的距离内发挥作用,以限制对周围细胞的损害。 原文出处:Novartis receives FDA Breakthrough Therapy designation for investigational 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC)
详见NEJM文章:Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer。 177Lu-PSMA-617是一种放射配体疗法(radioligand therapy,RLT),这类疗法结合了一种可与肿瘤表达的标志物结合的靶向性化合物和一种放射性同位素,可导致DNA损伤,抑制肿瘤生长和复制。这种治疗方法能够精确地向肿瘤细胞靶向递送...
3. Sartor O, et al.Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Sep 16;385(12):1091-1103. 4. 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)前列腺癌诊疗指南 ...
[1]Chi KN, Armstrong AJ, Krause BJ, et al. Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2024;85(4):382-391. doi...